Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K Meeting Abstract
| Authors: | O'Donnell, P. H.; Rosenberg, J. E.; Hoimes, C. J.; Petrylak, D. P.; Milowsky, M. I.; McKay, R. R.; Srinivas, S.; Friedlander, T. W.; Ramamurthy, C.; Bilen, M. A.; Burgess, E. F.; Mar, N.; Moon, H.; Geynisman, D. M.; George, S.; Carret, A. S.; Yu, Y.; Guseva, M.; Moreno, B. H.; Flaig, T. W. |
| Abstract Title: | Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.499 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 499 -- Accession Number: 162006744 -- Entry Date: In Process -- Revision Date: 20230223 -- Publication Type: Article -- Supplement Title: 2/21/2023 Supplement -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work